The cancer genomics revolution has rapidly expanded the inventory of somatic mutations characterizing human malignancies, highlighting a previously underappreciated extent of molecular variability between and within patients. Also in breast cancer, the most commonly diagnosed malignancy in women, this heterogeneity complicates the understanding of the stepwise sequence of pathogenic events and the design of effective and long-lasting target therapies. To disentangle this complexity and pinpoint which molecular perturbations are crucial to hijack the cellular machinery and lead to tumorigenesis and drug resistance, functional studies are needed in model systems that faithfully and comprehensively recapitulate all the salient aspects of their cognate human counterparts. Mouse models of breast cancer have been instrumental for the study of tumor initiation and drug response but also involve cost and time limitations that represent serious bottlenecks in translational research. To keep pace with the overwhelming amount of hypotheses that warrant in vivo testing, continuous refinement of current breast cancer models and implementation of new technologies is crucial. In this review, we summarize the current state of the art in modeling human breast cancer in mice, and we put forward our vision for future developments.
Breast cancer is the most commonly diagnosed invasive cancer worldwide, with more than 1.6 million new cases each year. Rather than a single disease, it represents a spectrum of malignancies, encompassing several distinct biological entities and subtypes, each associated with specific histopathological and molecular characteristics, responses to therapy, and clinical outcomes. Multiple taxonomies have been developed to divide breast cancer cases into different categories. Histopathological classification comprises several morphological and immunohistochemical phenotypes that can be further divided into different grades. Among the various morphologies, advanced mammary tumors mostly fall into the class of invasive ductal carcinomas (IDCs), followed by invasive lobular carcinomas (ILCs). Molecular classification based on gene expression patterns distinguishes five major subtypes of breast cancer: luminal A and B, ErbB2 þ , basal-like, and claudin-low (Perou et al. 2000) . Although these distinctions have proven useful for clinical decisionmaking, there are limitations in predicting disease prognosis and response to therapy. For example, a recent prospective, randomized phase III study showed that nearly half of the women with early breast cancer who are at high risk based on standard clinicopathological parameters might not require adjuvant chemotherapy (Cardoso et al. 2016) . The additional use of a 70-gene expression signa-ture may help to identify breast cancer patients who do not require adjuvant chemotherapy, but the identification of molecular signatures that reliably predict chemotherapy response remains elusive. Moreover, sequencing studies have shown that even within the same molecular subtype an extreme heterogeneity in the mutational landscape exists, which may account for discrepancies in prognosis and therapy response between different patients (Cancer Genome Atlas Network 2012; Stephens et al. 2012; Nik-Zainal et al. 2016) . Another complicating factor is intratumoral heterogeneity. Individual tumors are mosaics of multiple clones of neoplastic cells, each characterized by a distinct genetic makeup and differential responses to the selective pressures to which they are exposed, making the tumor mass not static but continuously shaped by a branching evolutionary process resembling Darwinian evolution. Distinguishing causal disease variants (driver mutations) from background alterations ( passenger mutations) is a major goal in breast cancer research, as it can pinpoint evolutionary conserved processes that mammary tumor cells apply during stepwise transformation and to which they might be addicted. To exploit these potential Achilles' heels, we require a comprehensive knowledge of how these signaling networks physiologically function, how they become aberrant, and how they can be directly or indirectly disrupted. Given this complexity, genetically engineered mouse models (GEMMs) of breast cancer, together with patientderived tumor xenografts (PDXs) and GEMM-derived tumor allografts, have proven valuable resources for deepening our understanding of how mammary tumors initiate, progress, metastasize, and respond to therapy in a physiologically relevant in vivo setting (Vargo-Gogola and Rosen 2007) . These mouse models are increasingly being used in longitudinal preclinical studies for translation of novel therapies to clinical testing. Moreover, GEMMs provide unique opportunities to infer causeeffect relationships on de novo induced malignancies growing in intact organisms, rather than correlative observations on end-stage patient tumor samples.
Over the past 15 years, our research has been focused on the generation and characterization of mouse models for two breast cancer subtypes: ILCs and basal-like IDCs. To achieve this, we engineered a number of tumor-specific driver mutations in the relevant target cells of mouse models, recapitulating the key dependencies of the resulting lesions to the corresponding deranged signaling pathways. In this review, we will discuss how these models can be used for functional dissection of tumorigenic cascades, unraveling new therapeutic vulnerabilities and mechanisms of therapy resistance-in particular, in light of the advent of new technologies such as clustered regularly interspersed short palindromic repeat (CRISPR)-Cas9 gene editing, which are opening new avenues in breast cancer modeling in mice.
INVASIVE LOBULAR BREAST CARCINOMA (ILC) MODELS
ILC accounts for 8% -14% of all breast cancer cases and is hallmarked at the morphological level by tumor cells growing in single "Indian files" within a dense fibrous stroma. This phenotype can be explained at the molecular level by loss of integrity of cell adherens junctions because of mutations or methylation of the CDH1 gene, which encodes the transmembrane protein E-cadherin (Martinez and Azzopardi 1979; Borst and Ingold 1993; Moll et al. 1993; Vos et al. 1997; Droufakou et al. 2001) . To our surprise, we found that mammary glandspecific Cre-mediated inactivation of Cdh1 alleles in mice was insufficient to induce mammary tumors, probably because normal cells undergo apoptosis and are counterselected when E-cadherin is lost (Boussadia et al. 2002; Derksen et al. 2006 Derksen et al. , 2011 . This prompted us to investigate which cooperating oncogenic events are required for malignant transformation of E-cadherin-deficient mammary epithelial cells. We have found that multifocal ILC formation is promoted by dual mammary-specific loss of E-cadherin and p53 (Derksen et al. 2006 (Derksen et al. , 2011 or E-cadherin and PTEN ( phosphatase and tensin homolog) (Boelens et al. 2016) , with tumor architecture and molecular profiles closely resembling their human ILC counterparts (Table 1) . However, it remains elusive which biological processes are rescued by codepletion of E-cadherin with one of these factors. To identify novel candidate cancer genes and networks that collaborate with E-cadherin loss in mammary tumorigenesis, we used the Sleeping Beauty (SB) transposon system (Collier et al. 2005; Dupuy et al. 2005) to perform an insertional mutagenesis screen in WAPcre;Cdh1 F/F mice (SM Kas, J de Ruiter, K Schipper, et al., in prep.) . Retrieval of recurrent integrations in SB-induced WAPcre;Cdh1 F/F mammary tumors identified common insertion sites in several genes, some known to be mutated in human ILC, suggesting that mutagenesis of these genes leads to malignant transformation. Moreover, analysis of enriched targeted pathways and mutually exclusive insertions revealed the regulation of the actin cytoskeleton as a completely novel oncogenic pathway in both mouse and human ILC.
Furthermore, recent genomic studies on collections of human ILCs have unveiled that, in addition to somatic inactivation of E-cadherin, activation of phosphoinositide 3-kinase (PI3K)/AKT signaling appears to be a common event in this breast cancer subtype (Ciriello et al. 2015; Desmedt et al. 2016; Michaut et al. 2016) . To validate these findings, we developed GEMMs of ILC that combine mammary gland -specific ablation of E-cadherin and activation of different oncogenic Pik3ca or Akt mutants (MHAM van Miltenburg, et al., in prep.) . To rapidly generate breast cancer models carrying these allelic variants, we used a novel strategy for fast-track production of GEMMs, called GEMM-ESC, which is based on Flprecombinase-mediated introduction of additional mutant alleles into the Col1a1 locus of embryonic stem cells (ESCs) derived from existing GEMMs (Huijbers et al. 2014) . Interestingly, the resulting mice showed rapid development of tumors with strong resemblance to human ILC in terms of morphology, gene expression, and invasiveness, on which we are now testing a panel of antican- cer therapeutics to identify promising genotype-specific drug sensitivities.
BASAL-LIKE BREAST CANCER MODELS
Basal-like breast cancers represent a heterogeneous class of malignancies with poor clinical outcome that accounts in total for 10% -15% of all breast cancer cases (Perou et al. 2000; Badve et al. 2011) . The majority of basal-like tumors lack expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) and are therefore referred to as triple-negative breast cancers. These tumors are not targetable with hormonal therapy or HER2 inhibitors, which leaves clinicians with only few effective options for therapeutic intervention.
Approximately 50% of basal-like breast cancers display a dysfunctional BRCA pathway because of germline or somatic mutations in BRCA1/2 or BRCA1 promoter hypermethylation (Cancer Genome Atlas Network 2012; Nik-Zainal et al. 2016) . Also a fraction of non-basal-like tumors are BRCA-deficient, mostly because of germline mutations in BRCA2. As these genes are crucial in the error-free repair of DNA double-strand breaks (DSBs) by homologous recombination (HR), BRCA defects are associated with chromosomal instability and hypersensitivity to DNA DSB-inducing drugs such as alkylating agents, poly ADP ribose polymerase inhibitors (PARPi), and radiotherapy (Jaspers et al. 2009; Bouwman and Jonkers 2012; M Barazas, et al., in prep.) . However, drug resistance mechanisms have been described in both clinical and preclinical studies of BRCA-associated tumors, posing serious concerns, as no other therapies are currently available for relapsing patients.
To study tumorigenesis and drug resistance mechanisms, we developed several conditional mouse models for BRCA1-and BRCA2-associated breast cancer (Evers and Jonkers 2006; Bouwman and Jonkers 2008) . In our K14cre;Brca1 F/F ;p53 F/F (KB1P) and K14cre;Brca2 F/F ; p53 F/F (KB2P) models, mammary inactivation of Brca1/ 2 is accompanied by loss of p53, as mutations in this tumor suppressor frequently co-occur with BRCA1/2 mutations in breast cancer (Jonkers et al. 2001; Liu et al. 2007 ). These mice develop mammary tumors after a latency period of 6-8 mo, suggesting that additional mutations are required for tumorigenesis (Table 1) . However, in contrast to ILC, in which point mutations are the most common somatic alterations, BRCA-mutated breast cancers are characterized by complex patterns of DNA copy number aberrations (CNAs), including translocations and gains/losses of entire chromosome arms (Vollebergh et al. 2012) . Using cross-species oncogenomics, we identified MYC amplification and RB1 loss as recurrent CNAs in both mouse and human BRCA1/2-mutated breast cancers . Exploiting the GEMM-ESC strategy, we could model conditional overexpression of MYC in our WAPcre;Brca1 F/F ;p53 F/F (WB1P) mouse model and found that mammary tumor development was indeed strongly accelerated compared to the original line (L Henneman, et al., in prep.) . Moreover, we observed that the number of CNAs in WB1P-MYC tumors was markedly reduced compared to WB1P tumors, showing only few recurrent CNAs that most likely harbor additional cancer drivers that collaborate with MYC overexpression and loss of BRCA1/p53 in breast tumorigenesis. We are currently performing cross-species comparisons of the recurrent CNAs in WB1P-MYC tumors with CNA profiles from human breast cancers to identify candidate cancer genes, which will be validated in the WB1P-MYC model. We believe that this iterative CNA profiling approach in progressively complex GEMMs will be instrumental for deciphering the key driver events in BRCA1-associated breast cancer and for uncovering novel therapeutic vulnerabilities.
PRECLINICAL TRIALS IN BRCA-ASSOCIATED BREAST CANCER MODELS
Although phase-I and -II clinical trials are mostly carried out in heavily pretreated volunteer patients who suffer from end-stage metastatic cancer, mouse models provide the opportunity to initiate treatment on naïve tumors in a clinically relevant in vivo setting. Treatment of mammary tumor-bearing KB1P mice with a panel of DSB-inducing agents showed heterogeneous responses between individual tumors but also marked differences in tumors treated with doxorubicin or docetaxel and those treated with cisplatin (Rottenberg et al. 2007 ). Although KB1P tumors eventually developed resistance to doxorubicin and docetaxel, no acquired resistance was observed for cisplatin. Even though these tumors could never be completely eradicated by maximum tolerated dose concentrations of cisplatin, the relapsing tumors remained responsive to subsequent treatments, resulting in a typical sawtooth tumor response. A major breakthrough came when it was found that spontaneous KB1P and KB2P tumors could be orthotopically allografted in syngeneic mice while maintaining their genetic characteristics and drug sensitivity profile. This approach reduced the time to produce cohorts of tumor-bearing mice from 7-9 mo to 4-6 wk, and enabled large-scale intervention studies in which the response of a single donor to different chemotherapeutic strategies could be compared, ruling out any intertumor heterogeneity (Fig. 1) . Intervention studies with the PARP inhibitor olaparib in KB1P tumor allografts led to the development of carboplatin and olaparib switch-maintenance therapy for BRCA1-mutated breast cancer (Rottenberg et al. 2008 ). This preclinical concept was confirmed in a clinical trial with olaparib maintenance therapy in BRCA-mutation carriers with platinum-sensitive ovarian cancer (Ledermann et al. 2012 (Ledermann et al. , 2014 and eventually led to clinical approval of olaparib (Deeks 2015) . Similarly, intervention studies in KB2P tumor allografts showed that alkylators such as nimustine could induce complete tumor eradication (Evers et al. 2010 ). Eradication of BRCA-mutated and BRCA-like cancer by high-dose alkylating chemotherapy was subsequently confirmed by retrospective analysis of data from clinical trials (Vollebergh et al. 2011 (Vollebergh et al. , 2014 Schouten et al. 2015) . These and other studies illustrate the utility of GEMMs of human cancer in translational cancer medicine.
PARPi RESISTANCE MECHANISMS IN BRCA-ASSOCIATED BREAST CANCER MODELS
In addition to accelerating preclinical trials, the KB1P and KB2P allograft platforms also enabled large-scale induction of acquired resistance to a drug of choice and subsequent identification of the underlying resistance mechanisms. The power of this approach was demonstrated with the PARP inhibitor olaparib, which was described to display selective toxicity against BRCA1/2-deficient cells (Bryant et al. 2005; Farmer et al. 2005) . Indeed, KB1P tumor allografts initially responded well to treatment but eventually relapsed and developed stable resistance (Rottenberg et al. 2008 ). This has provided a valuable collection of matched treatment-naïve and treatment-resistant tumors, which could be analyzed using next-generation sequencing or ( phospho)-proteomics, thereby taking advantage of the clean genetic background of inbred mice and the known genetic profile of treatment-naïve tumors. We found that Abcb1a and Abcb1b, encoding P-glycoprotein (P-gp) efflux pumps, were upregulated in resistant tumors and we confirmed that P-gp played an important role in mediating export of olaparib from tumor cells ( Fig. 2A ; Rottenberg et al. 2008 ). Resistance could be reversed when P-gp-mediated drug efflux was inhibited by coadministration of tariquidar. Although the clinical relevance of P-gp up-regulation as cause of drug resistance remains controversial (Amiri-Kordestani et al. 2012), expression of MDR1, the human counterpart of Abcb1, was recently found to be inversely correlated to olaparib response in human ovarian cancer cells (Vaidyanathan et al. 2016) . Such increased expression may result from complex genomic rearrangements that fuse a distant promoter to the MDR1 gene and thereby bypass the MDR1 promoter methylation (Patch et al. 2015) . The case of P-gp shows that a thorough mechanistic understanding is instrumental to combat resistant tumors-for example, by coadministration of tariquidar or by switching treatment to chemotherapeutics that are poor substrates for P-gp (Jaspers et al. 2013) .
To dissect P-gp-independent mechanisms of PARPi resistance, the KB1P mouse model was refined through germline genetic deletion of Mdr1 resulting in the K14cre;Brca1 F/F ;p53 F/F ;Mdr1a/b 2/2 (KB1PM) model (Jaspers et al. 2013) . Alternatively, KB1P tumors were treated with the PARP inhibitor AZD2461, which is a poor substrate for P-gp (Oplustil O'Connor et al. 2016) . PARPi resistance developed in these models despite the exclusion of P-gp-related mechanisms. To identify the underlying resistance mechanisms, next-generation sequencing data from treatment-naïve and PARPi-resistant tumors were combined with data from unbiased functional genetic screens in vitro. Through an insertional mutagenesis screen in conditional BRCA1-knockout mouse ESCs, we found that loss of 53BP1 rescues the proliferation defect, HR deficiency, and PARPi hypersensitivity of BRCA1-deficient cells by enhancing DSB end resection ( Fig. 2B ; Bouwman et al. 2010 ). This work from our laboratory and similar studies from the Nussenzweig laboratory (Bunting et al. 2010 ) have led to novel mechanistic insights in DSB repair and to date several downstream effector proteins of 53BP1 have been shown to suppress (Boersma et al. 2015; Xu et al. 2015) . Thorough analysis of mutational status and expression levels of 53BP1 and REV7 in PARPi-resistant KB1P(M) tumors confirmed that loss of 53BP1 or REV7 causes in vivo resistance to PARPi (Jaspers et al. 2013; Xu et al. 2015) . Interestingly, although KB1P(M) tumors with 53BP1 loss are crossresistant to topotecan and doxorubicin, they are still responsive to cisplatin, suggesting that platinum drugs may be a useful salvage therapy for this class of PARPi-resistant tumors (Jaspers et al. 2013) .
Although the majority of KB1P(M) tumors acquired PARPi resistance through restoration of HR, a substantial fraction of PARPi-resistant tumors remained defective in the formation of ionizing radiation-induced nuclear RAD51 foci (RAD51-IRIFs), which are a hallmark of HR. Moreover, when we analyzed the BRCA2-deficient KB2P tumors with acquired PARPi resistance, none of these showed restoration of HR as measured by RAD51-IRIF assays (E Gogola, et al., in prep.) . This suggests the existence of alternative resistance mechanisms. It was recently shown that chemoresistance in BRCA2-deficient cells might be mediated through protection of replication forks (RFs)-for instance, by depletion of PAX transcription activation domain interacting protein (PTIP) (Chaud-huri et al. 2016 ). It will be important to investigate whether RF protection is a common feature of PARPiresistant KB1P(M) and KB2P tumors.
In patients, mutated BRCA1 or BRCA2 proteins are often still expressed in tumors. Therefore, the large intragenic Brca1/2 deletions present in KB1P(M) and KB2P tumors-although instrumental in genetic studiesmight not fully recapitulate the biology of BRCA-associated tumors in mutation carriers. To this end, we generated several mouse models mimicking pathogenic BRCA1 variants that are often encountered in the clinic (Drost et al. 2011 (Drost et al. , 2016 . These models provided evidence that the type and location of the BRCA1 mutation can have significant implications for the response of these tumors to DSB-inducing agents and PARPi. It was found that tumor cells harboring the BRCA1 185delAG allelic variant, which was modeled in mice by a Brca1 185stop allele, can use a downstream alternative start site leading to the expression of a RING-less BRCA1 protein (Drost et al. 2016) . This RING-less BRCA1 protein maintains hypomorphic HR activity, which is sufficient to induce a poor response to platinum drugs or olaparib. These results illustrate the importance of testing BRCA1 allelic variants not only for genetic counseling but also for providing adequate treatment.
PDX models provide a solution to narrow the gap between mouse and human cancer biology and as such represent a novel in vivo platform for studying therapy response and resistance. Although PDX models have been relatively difficult to generate in the past, recent advances have made it possible to generate PDX biobanks covering a heterogeneous population of tumors (Hidalgo et al. 2014) . Once the (epi)genetic landscape of a PDX model is characterized, this provides an effective tool to study the drug response of a specific tumor and to predict which resistance mechanisms might evolve during treatment. We recently demonstrated the feasibility of such an approach by treatment of PDX models of BRCA1-deficient breast cancer with alkylating agents or olaparib (Ter Brugge et al. 2016 ). Similar to the GEMM tumors, these PDX tumors generally responded well to treatment, but eventually developed resistance. The underlying mechanism was dependent on the type of BRCA1 inactivation: Whereas therapy-resistant BRCA1methylated PDX tumors frequently showed BRCA1 promoter demethylation, BRCA1-mutated tumors acquired resistance via genetic reversion through secondary mutations that restored the BRCA1 reading frame (Fig. 2C,D) . These events have also been known to mediate resistance in ovarian cancer patients (Swisher et al. 2008; Patch et al. 2015) , showing the predictive potential of PDX models. The PDX models also revealed a novel resistance mechanism involving gene fusions that placed BRCA1 under transcriptional control of a heterologous promoter. It is intriguing that resistance mechanisms in PDX tumors are mainly centered on re-expression of functional BRCA1 protein rather than inactivation of 53BP1 or related factors, highlighting the strong selective pressure on complete restoration of BRCA1 function when BRCA1deficient tumor cells are exposed to DSB-inducing therapy. However, a fraction of tumors acquired resistance in the absence of BRCA1 reexpression, showing that alternative resistance mechanisms also occur in PDX models.
Taken together, these studies illustrate the power of mouse models in unraveling resistance mechanisms before their emergence in patients. It will be important to investigate to what extent these play a role in the clinic. This is not trivial, as they likely occur in a limited group of BRCA patients and thus require careful patient selection. It is noteworthy that resistance caused by mutations in additional DNA repair genes such as 53BP1 or REV7 might expose new treatment vulnerabilities (e.g., sensitivity to combined PARP and ataxia telangiectasia mutated [ATM] inhibition [Bunting et al. 2010] ). It will therefore be important to determine if and how each resistance mechanism can be exploited therapeutically. Ultimately, this may provide a framework for oncologists to combat resistance in the clinic.
NONGERMLINE GEMMs OF BREAST CANCER
Large-scale cancer genome sequencing studies and forward genetic screens have jointly boosted the discrimination between passenger and driver mutations and the identification of genetic determinants of drug sensitivity and resistance in breast cancer. The systematic translation of these long catalogs of structural aberrations into functional information requires the assessment of the pathophysiological impact of candidate gene perturbations in reliable preclinical models. This inevitably poses a practical challenge for in vivo validation experiments, because of the considerable costs and time requirements associated with establishing new breast cancer GEMMs. Novel technologies, especially CRISPR -Cas9-based methods, are revolutionizing the genetic engineering field by providing fast ways for precise and efficient ESC manipulation and GEMM development (Wang et al. 2013 ). However, as sequencing expenses of human tumors keep decreasing, research will shift from testing oncogenicity of single driver alleles to investigating the impact of multiple allelic variants on tumor development and therapy response. At the same time, forward genetics strategies will evolve from genome-wide approaches based on simple gene (in)activation to more refined chemical mutagenesis and gene-based CRISPR screens capable of identifying novel hypomorphic, dominant-negative, and separation-offunction mutants at the base pair level. We foresee that the number of testable hypotheses will far exceed the capacity of transgenic facilities, warranting the development of new in vivo platforms for systematic, multiplexed interrogation of putative cancer drivers. Ideally, such models should sort out current temporal and economical limitations of GEMM establishment and bypass extensive mouse husbandry but also allow a high degree of manipulability and flexibility by enabling spatiotemporal control of tumor initiation and progression.
To develop such a platform for breast cancer, we explored the possibility of nongermline modeling of mammary tumors by exploiting intraductal injection in the nipple of adult female mice as a way to deliver high-titer lentiviral or adenoviral preparations to mammary epithelium and achieve somatic genome engineering. We have shown that intraductally injected lentiviruses can target tumor-initiating cells of both the basal and the luminal compartment, allowing modeling of both ILC and basallike tumors in mice with the corresponding set of relevant predisposing alleles. For example, intraductal injection of Cre-encoding lentiviruses in Cdh1 F/F ;Pten F/F mice induced the formation of ILCs that were undistinguishable from the ILCs arising in the original WAPcre;Cdh1 F/F ; Pten F/F model (Annunziato et al. 2016) . Somatic Cre delivery may more accurately recapitulate sporadic tumor initiation by allowing titratable and spatiotemporally controlled delivery of viruses to mammary tissue. Moreover, targeting specificity can be modulated by using viruses with cell type -specific promoters and/or posttranscriptional control elements (Tao et al. 2014) .
Importantly, the potential of nongermline modeling extends far beyond simple exogenous administration of Cre to established GEMMs. A diverse array of viral and nonviral constructs can be employed to achieve desired permutations of specific candidate genes even in the absence of germline conditional alleles: (a) vectors for overexpression of wild-type, truncated, or mutated cDNAs; (b) vectors for shRNA-mediated down-regulation or CRISPRmediated (epi)genetic manipulation of single or multiple endogenous genes (Sander and Joung 2014) ; (c) CRISPR vectors for modeling large chromosomal rearrangements (Maddalo et al. 2014) ; and (d) vectors for tagging and imaging of tumors (Fig. 3) . Regarding CRISPR-based in vivo editing approaches, we and others have shown that somatic delivery of the bacterial Cas9 protein has the considerable drawback of eliciting strong and specific immune responses in immunocompetent animals (Wang et al. 2015; Annunziato et al. 2016 ). This problem can be overcome by employing knock-in models that are tolerant to Cas9 because of constitutive or conditional expression of Cas9 or catalytically inactive dCas9-effector fusions (which allow for transcriptional silencing/activation of endogenous alleles) (Platt et al. 2014; Sánchez-Rivera and Jacks 2015) . We have recently reported somatic induction of oncogenic loss-of-function mutations in mice with mammary-specific expression of Cas9 by intraductal injection of single-guide RNA (sgRNA)-encoding lentiviruses, which eventually led to ILC formation (Annunziato et al. 2016) .
MAMMARY TUMOR ORGANOIDS
Another exciting technological breakthrough came from the possibility to derive organotypic 3D culture mod-els of normal and malignant mammary tissue. Human and murine tumor organoid cultures retain key features of donor tumors, including cellular heterogeneity and molecular characteristics (Clevers 2016; Fatehullah et al. 2016) . Compared to the laborious and time-consuming establishment of 2D cell lines, which requires adaptation to monolayer growth on plastic surfaces, tumor organoid cultures are much easier to derive, can be expanded indefinitely ex vivo, and upon xenografting/allografting undergo polyclonal expansion and efficiently produce tumors that preserve the cellular heterogeneity and drug response profiles of the original tumors (AA Duarte, E Gogola, N Sachs, et al., in prep.) . For example, we found the differential olaparib sensitivity of isogenic treatment-naïve and PARPi-resistant KB1P mammary tumors to be stable upon organoid derivation and subsequent retransplantation. Using CRISPR -Cas9 technology, we were able to introduce Trp53bp1 frameshift mutations in the treatment-naïve KB1P organoid line and demonstrate that this permutation rendered the organoid-derived tumors refractory to olaparib. We are exploiting the KB1P tumor organoid platform to test additional candidate drug resistance genes for their in vivo relevance, including candidates retrieved from forward genetic screens and from sequencing of drug-resistant tumors (Fig. 4) given the short latency period and polyclonal tumor outgrowth, GEMM and PDX tumor organoids are particularly amenable for in vivo genetic screens using short-hairpin RNA (shRNA), CRISPR, CRISPRi, and CRISPRa libraries.
CONCLUSION
A number of known and unknown biological discrepancies inevitably exist between mouse models and humans. Moreover, refinements in mouse modeling should be compliant with practical and ethical issues associated with model establishment. Nevertheless, the systematic and synergistic deployment of complementary in vitro and in vivo platforms (GEMMs, PDX models, organoids, nongermline models) is envisioned to provide a quantum leap in the oncology arena and in breast cancer research in particular. Cutting-edge mouse cancer clinics will enable so-called coclinical trials, in which clinical studies will be paralleled by preclinical intervention studies in mouse avatars. This will allow clinicians to infer in real-time genotype-specific drug response profiles from mouse models and design more effective and long-lasting patient-tailored treatment schemes. The emergence of drug resistance is an invariable and intrinsic consequence of Darwinian tumor growth dynamics, but instead of "whack-a-mole" treatment schedules, coclinical trials could assist in the design of more sophisticated and personalized regimens in which tumors are forced through evolutionary bottlenecks that render them exquisitely sensitive to secondary therapies. Reiteration of this adaptive process is possible only by the use of ever-smarter mouse models, which will ultimately lead to improved long-term management of this devastating disease.
